- (Abstract #1107) Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study. C. Moskowitz. Monday, Dec. 5, 5 p.m. PST (session: 4:30-6 p.m. PST). Location: Room 6B.
- (Abstract #1108) Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Long-Term Efficacy from the Phase 1b Keynote-013 Study. P. Armand. Monday, Dec. 5, 5:15 p.m. PST (session: 4:30-6 p.m. PST). Location: Room 6B.
- (Abstract #619) Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial. P. Zinzani. Monday, Dec. 5, 7 a.m. PST (session: 7-8:30 a.m. PST). Location: Room 6B.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data regarding the investigational use of KEYTRUDA ® (pembrolizumab), the company's anti-PD-1 therapy, in patients with a range of blood cancers including classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma, will be presented at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, Dec. 3-6. "There is an urgent need for new treatment approaches in blood cancers, especially for those patients who have relapsed or not responded to current therapies," said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. "We hope to learn that PD-1-directed immunotherapy may be used to help patients suffering from these difficult to treat malignancies." The KEYTRUDA clinical development program includes more than 30 tumor types in more than 360 clinical trials, including over 200 trials that combine KEYTRUDA with other cancer treatments. For hematologic malignancies specifically, Merck is conducting broad immuno-oncology research assessing the role of monotherapy and combination regimens with KEYTRUDA. The program includes nearly 40 ongoing studies - several of which are registration-enabling trials - across more than 20 hematologic disease subtypes, including leukemia, lymphomas, and myeloma. Below is a select list of KEYTRUDA data to be featured in oral presentations (all at the San Diego Convention Center):